Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I received the shareholder letter from CUBT just as was stated by IR. So all the discussion about the company sending the letter to select shareholders was pure hysteria.
Added more at .0802. I’ll take it. When this thing runs at some point the 1/2 cent difference won’t matter.
Am I missing something or did oxnous not say .075?
Strong buy oxnous! Smart move. You benefited from the fear mongering.
LOL about diluting shares. Every good company offers shares to the people that make things happen in the company. Producers get shares in the company. They ain’t making any salary so they have to use some form of compensation to attract top talent. And it is usually shares. Period.
Don’t let the fear mongers tempt you into selling your shares. The hysteria here is ridiculous.
Yep and thinking it was a buyer who knows a thing about Catherine Sohn and wanted in. Not a coincidence the recent move to .13 happened after she was announced as an advisor to the board and CEO.
Well stated. My feeling put your money where your mouth is. If you don’t believe in what they are doing then sell the stock. Period. Notice to those vulnerable to fear. Do your due diligence and don’t let fear-mongering get to you if you believe in what they are doing. For me I remain Long CUBT.
Looks like there will be some cheap shares available Monday. I’m buying. Bruised egos. LOL. When a minority of owners own the majority of the shares they call the shots. Not OTC buyers who think a little bit too much of themselves. This management team knows what they’re doing. Don’t buy into the fear mongering going on here. Because guess who will be buying up your shares you sell on fear? They will be. Cheers and GLTA.
I don’t think they are considering this now. The pdf said they are authorized to do a split out to 2023 if my memory serves right on what the pdf stated posted here on the board. In my communications with the company, seems going to a big board has always been seen as a future possibility. The hit on the stock price today hurt no doubt. I remain confident this team knows what they are doing. All this imo.
Yet you correct student of the game and not Pepe on being wrong. LOL.
Nope. Do your homework and you will see. They have three main drugs in the pipeline, a fourth if you include the use of IMT504 in the Covid vaccine for patients with kidney issues or other auto-immune issues. All three of these deals were done in 2020 which is less than two years ago. So when you say several what are talking about exactly.
These CUBT bear posts here are comical.
And then again it may not be the high for a while. Things can turn on a dime. Be ready, that’s all I have to say.
LOL. Buy signal to drive price down. Silence when it run. Rinse and repeat.
These are the days I keep adding. Low volume when someone pulls back price.
Lot more shares bought above .12 the other day on over 5M volume than the low volume selling today 300k. Telling to me.
Old CUBT shorty will get burned eventually. Looks like market makers or traders manipulating price on low volume.
Added at .1105.
Yes it is!
That buy signal was working overtime leading up today. LOL.
The point is that any argument about companies not having an office in the current pandemic environment is a joke.
The following comment really makes comments about CUBT not having an “office” irrelevant, if not straight up laughable.
“One size fits all is dead. The corporate headquarters as we knew it, 9-5, five days a week, corporate HQ, I don’t think we’re ever going back to that,” said WeWork executive chairman Marcelo Claure at the recent CNBC @Work Summit.
I’m buying the dips. Price drop on low volume. Very common. When she goes she will really go. Good time to buy imo.
CUBT buy signals all over the place!!!
Added a few more today. Buying dips until she goes.
Correct me if I am wrong, but I don’t believe there was ever any conviction. Is that right? Yes it is! It’s a non issue. Yep n this great country of ours one is innocent until proven guilty. Guilty means conviction. Anything else is just meaningless.
It’s amusing to me that two words CEO Garr said set this board ablaze with unwarranted criticism…”probably not”, when asked if the IND would be filed by EOY for Metformin.
Reasoning he gave was around supply chain issues on needed materials. A simple Google search on supply chain issues currently in the U.S. would help those understand some of the challenges and validate the reasons for the delay on the IND. Supply chain issues are very real, largely impacted by Covid and will continue to impact the economy.
In addition to that it is a well known fact that many people in the FDA had been working from their virtual offices from home during Covid which also slowed progress down on many initiatives in the drug space.
I am VERY confident this group will get the IND done. In the meantime they continue to work on their three other drug solutions, which now includes a Covid vaccine for patients with Kidney issues and impaired immune systems similar to what took the life of Colin Powell yesterday. This solution could be advanced by the Operation Warp Speed initiative similar to other Covid vaccines, which could move things along quicker than one might think.
And now to add Dr. Catherine Sohn as special advisor to the Board and CEO is icing on the cake. She is a game changer. She surely would have done her due diligence before putting her reputation on the line by joining in this advisory role. Connect the dots. It’s all coming together.
The cup for me here is half full, not half empty. Choose your own path. For me, with this all star cast and business plan I am LONG CUBT. Patience will pay off here IMO.
Richard Garr is a straight up CEO. Completely agree. Any comments to the contrary are spoken in complete ignorance. They have no clue who this man is.
Very excited to see Dr. Sohn overseeing all three pipelines of drugs. She is an absolute star to add to their team. She would not be putting her reputation on the line for some scam that people are stating here. Gotta believe she will also contribute to future partnerships given her background. Good things ahead. Long CUBT!!!
So what Oxnous is saying here is that shares held by insiders can’t be sold this November. Any questions?
Excellent video. The team assembled here is world class. Pretty amazing. Very refreshing when you look at the shady characters leading other OTC companies. This will not be an OTC stock down the road. Big things ahead for this sleeping giant.
Back to posts about wife beating and the office. Was hearing these arguments when it traded at .02, 500% ROI ago. LOL. CUBT has strategy in motion, lead by a world class leadership team. Pieces all coming together. Buy signal working overtime today. Good things must lie ahead.
This is pretty much how the entire stock market works. The real question will be around the value of company as they execute. We shall see. Nothing wrong with trading some shares while holding a core position when the prices goes up. Typically a new higher low will be established - seems this .10-.11 range after prior being below a penny is the new low after going to .20. Have your strategy in place.
Bought a handful at .1011 today. Will continue to buy if it goes lower. Closing in on 3.2M shares now. Patience will pay off on this one. Now is the time to add imo.
Market makers holding it back. They have a lot shares and they hit the low bid in hopes of triggering a sell off and buying cheap shares. Do really need to ask this
In 2015, Retrophin sold a PRV to Sanofi for around $245 million, and later the same year, United Therapeutics Corp. sold a PRV for a drug for a rare pediatric disease to AbbVie Inc. for $350 million. Rabies as one would know if they did any due diligence is a real problem outside of the United States, mainly in under served countries. Kudos to CUBT for pursuing this while other pharma companies choose to focus mainly on opioids and vaccines. Getting priority review for IMT504’s use in a vaccine targeting those with kidney problems through a rabies PRV would only compound the value of said PRV. Nice try on your bear thesis.
If someone is going to make the comment that Covid is on the way out, they should really explain what they mean. People are dying every day from the virus and other variants will surely appear like others here have stated. Saying Covid is on the way out does not seem to based on fact. CUBT adding another application to IMT504’s use and potentially getting priority review if a PVR is granted for rabies is a savvy business move and consistent with their rare disease model in targeting kidney patients.
Yes indeed buy signals everywhere. That PR truck a nerve today. Wink wink.